← Back to Search

Other

ReNu Injection for Plantar Fasciitis

N/A
Waitlist Available
Led By Alan Ng, DPM, FACFAS
Research Sponsored by NuTech Medical, Inc
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a new injection called ReNu™ to see if it can help people with plantar fasciitis, a condition that causes foot pain and swelling. The study will compare ReNu™ to the usual treatment, which is a corticosteroid injection. Researchers will check how well each treatment works by asking patients about their pain and satisfaction over time.

Eligible Conditions
  • Plantar Fasciitis

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Secondary study objectives
Return to Normal Function between treatment groups

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: ReNu InjectionExperimental Treatment1 Intervention
Plantar Fascia injection with ReNu. ReNu is an allograft tissue composed of particularized amniotic membrane and cell from the amniotic fluid.
Group II: Corticosteroid InjectionActive Control1 Intervention
Plantar Fascia injection with Corticosteroids.

Find a Location

Who is running the clinical trial?

MileStone Research OrganizationIndustry Sponsor
1 Previous Clinical Trials
5 Total Patients Enrolled
OrganogenesisIndustry Sponsor
36 Previous Clinical Trials
4,290 Total Patients Enrolled
NuTech Medical, IncLead Sponsor
10 Previous Clinical Trials
471 Total Patients Enrolled
~17 spots leftby Oct 2025